HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Banani, S. J. Articles by Geramizadeh, B. Search for Related Content PubMed PubMed Citation Articles by Banani, S. J. Articles by Geramizadeh, B.

S. JAVAD BANANI, M.D., is Physician, Department of Internal Medicine, Namazi Hospital (NH), Shiraz University of Medical Sciences (SUMS), Shiraz, Iran, and a Ph.D. degree candidate, Department of Medicine, Cancer Research Center, University of British Columbia, Vancouver, Canada; at the time of this study he was Supervisor, Fars Health Organization, Iran. KAMRAN B. LANKARANI, M.D., is Professor of Gastroenterology, SUMS, and Minister of Health, Ministry of Health, Tehran, Iran; at the time of this study he was Chairman, Department of Internal Medicine, SUMS. ALIREZA TAGHAVI, M.D., is Assistant Professor of Gastroenterology, Department of Internal Medicine, SUMS. MOHAMMAD HADI BAGHERI, M.D., is Associate Professor of Clinical Radiology; SEPIDEH SEFIDBAKHT, M.D., is Assistant Professor of Clinical Radiology, Department of Radiology and Imaging Studies; and BITA GERAMIZADEH, M.D., is Professor of Clinical Pathology, Transplant Research Center, NH, SUMS.

Address correspondence to Dr. Banani at Namazi Hospital, P.O. Box 71345-1511, Shiraz, Iran (sjbanani{at}yahoo.com).

Purpose. The clinical effects of metoclopramide oral solution and tablets in patients with dysmotility-like dyspepsia (DLD) were compared. Methods. In a prospective study, 63 patients with DLD, selected according to Rome II criteria and randomly divided into three groups, received metoclopramide tablets 5 mg t.i.d., metoclopramide oral solution 2 mg t.i.d., or placebo for one week. Assessment was based on symptom score determined by interviews and on gastric emptying time measured by ultrasonography before and after drug consumption. Two antral and stomach body biopsies were taken to evaluate infection with Helicobacter pylori and the intensity of gastritis. Results. Symptom score and gastric emptying time were significantly reduced in both metoclopramide groups (p < 0.05) but not in the control group. Patients receiving the oral solution had a greater reduction in the symptom score than those receiving tablets (p < 0.05). The absence or presence of and intensity of gastritis or H. pylori infection had no correlation with the symptom scores or gastric emptying times. Conclusion. Metoclopramide oral solution 2 mg t.i.d. was at least as effective as metoclopramide tablets 5 mg t.i.d. in reducing symptoms of DLD and gastric emptying time. Index terms: Dosage forms; Dyspepsia; Gastric emptying; Gastrointestinal drugs; Helicobacter infections; Metoclopramide; Solutions; Tablets